• SP2509: LSD1 Inhibitor for Acute Myeloid Leukemia Research

  2026-03-07

  SP2509 is a highly selective LSD1 antagonist that enables precise modulation of cancer epigenetics in acute myeloid leukemia (AML) models. Its potent, nanomolar inhibition and workflow-friendly properties support robust apoptosis induction and differentiation studies for translational research.

• Decitabine: DNA Methyltransferase Inhibitor for Cancer Ep...

  2026-03-06

  Decitabine (5-Aza-2'-deoxycytidine) from APExBIO stands at the forefront of cancer epigenetics, enabling precise DNA hypomethylation and robust tumor suppressor gene reactivation in both hematopoietic malignancy and solid tumor models. This guide delivers actionable workflows, troubleshooting strategies, and advanced applications to maximize research impact and reproducibility.

• Trichostatin A: HDAC Inhibitor Workflows for Cutting-Edge...

  2026-03-06

  Trichostatin A (TSA) from APExBIO stands as the gold-standard HDAC inhibitor for researchers driving breakthroughs in cancer biology and epigenetic regulation. This article delivers actionable experimental workflows, advanced troubleshooting, and comparative analysis, enabling scientists to maximize the reproducibility and impact of TSA in translational research.

• Trichostatin A (TSA): Mechanistic Leverage and Strategic ...

  2026-03-05

  This thought-leadership article explores the mechanistic power and translational promise of Trichostatin A (TSA), a benchmark histone deacetylase inhibitor (HDACi) for epigenetic research and cancer therapy. Integrating recent evidence and strategic guidance, it charts a course for researchers seeking to harness HDAC inhibition to address unmet clinical needs—particularly in malignant and refractory cancers. Contextualizing APExBIO’s Trichostatin A within current workflows and combination therapy innovations, the piece advances the discussion beyond standard product descriptions, equipping translational scientists with actionable insights.

• Scenario-Driven Solutions for BET Inhibition with I-BET-7...

  2026-03-05

  This article provides scenario-based, evidence-backed guidance for deploying I-BET-762 (SKU B1498) in cell viability, proliferation, and ferroptosis assays. Drawing on recent data and practical laboratory challenges, it demonstrates how I-BET-762 delivers reliable, reproducible results in epigenetic and cancer biology workflows, and offers candid advice on vendor selection and protocol optimization.

• EPZ-6438: Selective EZH2 Inhibitor for Epigenetic Cancer ...

  2026-03-04

  EPZ-6438 sets a new benchmark for precision epigenetic modulation by targeting EZH2-driven transcriptional repression in cancer models. Its robust selectivity and workflow flexibility empower researchers to dissect the PRC2 pathway and advance translational oncology, especially in HPV-associated and SMARCB1-deficient tumors.

• GSK343 and the PRC2-APEX2 Axis: Mechanistic Insights and ...

  2026-03-04

  This thought-leadership article, presented by APExBIO, delves into the mechanistic and translational landscape of GSK343, a potent and selective EZH2 inhibitor. We bridge recent discoveries on chromatin regulation, DNA repair, and telomerase (TERT) expression—including the seminal role of APEX2 in stem cell maintenance—with practical strategies for translational researchers. By contextualizing GSK343 within the evolving competitive landscape and highlighting its unique potential in epigenetic cancer research, this piece provides actionable guidance and a visionary roadmap for experimental design and clinical translation.

• Trichostatin A: HDAC Inhibitor for Advanced Epigenetic Re...

  2026-03-03

  Trichostatin A (TSA) from APExBIO empowers cancer and epigenetic researchers with robust, reproducible HDAC inhibition for advanced cellular and molecular workflows. This guide details stepwise protocols, novel experimental combinations, and actionable troubleshooting tips for maximizing TSA's impact in breast cancer and malignant meningioma models.

• NADH (Reduced Nicotinamide Adenine Dinucleotide, CAS No. ...

  2026-03-03

  NADH, a key cellular energy metabolism coenzyme, is vital for mitochondrial electron transport chain research and as a biomarker in redox biology. APExBIO’s NADH (SKU: C8749) provides a rigorously characterized reagent for reproducible research in metabolic disease and translational applications.

• Optimizing Epigenetic Assays: Scenario Solutions with GSK...

  2026-03-02

  This article delivers scenario-driven guidance for biomedical researchers using GSK J4 HCl (SKU A4190) in cell-based epigenetic and viability assays. Through evidence-based Q&A blocks, discover how this JMJD3 inhibitor—an ethyl ester derivative of GSK J1—addresses real lab challenges, ensuring reproducibility and robust data in chromatin remodeling and immune modulation research.

• RG108 DNA Methyltransferase Inhibitor: Practical Solution...

  2026-03-02

  This scenario-driven article addresses common laboratory challenges in epigenetic gene regulation and cell assay workflows, providing actionable guidance for researchers using RG108 DNA Methyltransferase Inhibitor (SKU A1913). Drawing on peer-reviewed data and hands-on best practices, the article demonstrates how SKU A1913 from APExBIO ensures reproducible, high-fidelity results across diverse epigenetics applications.

• GSK J4 HCl: Transforming Epigenetic Regulation Research

  2026-03-01

  GSK J4 HCl stands out as a cell-permeable, robust JMJD3 inhibitor, streamlining experimental workflows in chromatin remodeling and inflammatory disorder research. Discover how this ethyl ester derivative of GSK J1 empowers high-impact studies—from intricate immune modulation to pediatric brainstem glioma modeling—while overcoming key technical roadblocks in epigenetic regulation.

• BRD4770: G9a Histone Methyltransferase Inhibitor for Epig...

  2026-02-28

  BRD4770 is a potent, cell-permeable G9a histone methyltransferase inhibitor used as an epigenetic modulator for cancer research. It precisely reduces H3K9 methylation and induces senescence in cancer cell models, notably PANC-1, supporting its utility in studies of tumorigenesis and epigenetic regulation.

• GSK126: Selective EZH2/PRC2 Inhibitor for Cancer Epigenet...

  2026-02-27

  GSK126 is a highly potent, selective EZH2 inhibitor that blocks H3K27me3, a key epigenetic mark in cancer progression. This article details GSK126’s mechanism, evidentiary basis, and practical parameters for oncology and epigenetics workflows. Its unique selectivity for EZH2-mutant contexts positions it as a benchmark tool in cancer epigenetics research.

• Trichostatin A (TSA): Unraveling HDAC Inhibition and Meta...

  2026-02-27

  Explore how Trichostatin A (TSA), a potent histone deacetylase inhibitor, bridges epigenetic regulation and mitochondrial metabolism in cancer research. Gain new insights into the interplay of HDAC inhibition, ferroptosis, and cell cycle control for next-generation epigenetic therapy.

16562 records 1/1105 page Next 12345 下5页 Last page